NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

AXSM

Axsome Therapeutics Inc

May 08 • 04:00PM ET

108.86

Dollar change -2.00
Percentage change -1.80	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB ACAD VRTX ALKS NBIX BHVN SAGE PRTA AVDL RARE

| Held by: VTI VB IWM VXF VBK IWO IBB SCHA VTWO IHE

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.77	Insider Own	17.82%	Shs Outstand	49.22M	Perf Week	-3.01%
Market Cap	5.36B	Forward P/E	58.20	EPS next Y	1.87	Insider Trans	-0.17%	Shs Float	40.46M	Perf Month	11.59%
Income	-278.27M	PEG	-	EPS next Q	-1.06	Inst Own	79.98%	Short Float	10.93%	Perf Quarter	-0.58%
Sales	432.16M	P/S	12.40	EPS this Y	43.81%	Inst Trans	-1.41%	Short Ratio	5.11	Perf Half Y	24.77%
Book/sh	1.08	P/B	100.70	EPS next Y	155.57%	ROA	-48.72%	Short Interest	4.42M	Perf Year	43.35%
Cash/sh	6.11	P/C	17.81	EPS next 5Y	-	ROE	-282.16%	52W Range	64.11 - 139.13	Perf YTD	28.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-24.44%	ROI	-106.14%	52W High	-21.76%	Beta	0.52
Dividend TTM	-	Quick Ratio	1.96	Sales past 5Y	96.67%	Gross Margin	89.61%	52W Low	69.80%	ATR (14)	4.51
Dividend Ex-Date	-	Current Ratio	2.03	EPS Y/Y TTM	9.65%	Oper. Margin	-55.36%	RSI (14)	48.27	Volatility	4.18% 4.33%
Employees	683	Debt/Eq	3.97	Sales Y/Y TTM	72.16%	Profit Margin	-64.39%	Recom	1.06	Target Price	177.55
Option/Short	Yes / Yes	LT Debt/Eq	3.93	EPS Q/Q	15.71%	Payout	-	Rel Volume	0.67	Prev Close	110.86
Sales Surprise	1.94%	EPS Surprise	9.71%	Sales Q/Q	61.95%	Earnings	May 05 BMO	Avg Volume	865.55K	Price	108.86
SMA20	1.98%	SMA50	-4.43%	SMA200	9.26%	Trades		Volume	576,234	Change	-1.80%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-07-25	Initiated	Jefferies	Buy	$200
Feb-11-25	Initiated	Deutsche Bank	Buy	$176
Dec-31-24	Reiterated	Mizuho	Outperform	$124 → $122
Sep-03-24	Initiated	Wells Fargo	Overweight	$140
Aug-06-24	Upgrade	BofA Securities	Neutral → Buy	$95 → $106
Jul-22-24	Initiated	Needham	Buy	$130
Apr-29-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$90 → $115
Mar-19-24	Initiated	Robert W. Baird	Outperform	$108
Feb-06-24	Initiated	UBS	Buy	$111
Jan-25-24	Initiated	RBC Capital Mkts	Outperform	$126
Dec-13-23	Initiated	Citigroup	Buy	$125
Aug-08-23	Upgrade	BofA Securities	Underperform → Neutral	$59 → $81
Jan-05-23	Initiated	Piper Sandler	Neutral	$75
Nov-01-22	Initiated	Loop Capital	Buy	$95
Sep-07-22	Resumed	Mizuho	Buy	$49 → $76
Aug-10-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$105 → $34
Jun-10-21	Initiated	Berenberg	Buy	$112
Jan-08-21	Initiated	Jefferies	Buy	$129
Dec-16-20	Initiated	Mizuho	Buy	$120
Sep-29-20	Initiated	BofA Securities	Underperform	$66

Show Previous Ratings

May-06-25 09:39AM	AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
03:02AM	Axsome Therapeutics Inc (AXSM) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
12:24AM	Q1 2025 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-05-25 11:44AM	Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:15AM	Loading…
08:15AM	Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-01-25 07:00AM	Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month (GlobeNewswire)
Apr-30-25 10:01AM	TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth (Zacks)
Apr-28-25 10:00AM	Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline (Zacks)
Apr-22-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-10-25 09:52AM	Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last? (Zacks) -5.92%
06:18AM	Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy (TipRanks)
Apr-08-25 07:00AM	Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 (GlobeNewswire)
Apr-04-25 07:00AM	Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) -8.37%
03:00PM	Loading…
Apr-02-25 03:00PM	Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More (Zacks)
11:29AM	AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol (Zacks)
09:33AM	Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 (Zacks)
Apr-01-25 04:04PM	Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week (Investor's Business Daily)
01:23PM	Why Shares of Axsome Therapeutics Slumped Today (Motley Fool)
07:00AM	Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS) (GlobeNewswire)
Mar-26-25 11:51AM	AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint (Zacks)
Mar-25-25 06:47PM	Why Pharma and Biotech Stocks Got Thrashed on Tuesday (Motley Fool) -6.82%
12:53PM	IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. (Investor's Business Daily)
07:00AM	Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint (GlobeNewswire)
Mar-21-25 11:36AM	Axsome: The Alzheimer's Agitation Program For AXS-05 (SeekingAlpha)
Mar-20-25 12:00PM	Lazard US Equity Concentrated Portfolio Q4 2024 Commentary (SeekingAlpha)
11:30AM	Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-19-25 12:14PM	HRMY Down 10.8% in Six Months: How Should You Play the Stock? (Zacks)
Mar-14-25 10:32AM	Is Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock in 2025? (Insider Monkey)
07:00AM	Loading…
Mar-05-25 07:00AM	Axsome Therapeutics Settles Sunosi (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA (GlobeNewswire)
Mar-03-25 07:00AM	Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer's Disease Agitation Supporting NDA Submission (GlobeNewswire)
Mar-01-25 05:04PM	Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-26-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-24-25 01:34PM	Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs (Benzinga) -5.10%
07:00AM	Axsome Therapeutics Announces SYMBRAVO (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors (GlobeNewswire)
Feb-23-25 03:09PM	Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-21-25 04:58PM	These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50 (Investor's Business Daily) +6.70% -5.10%
Feb-19-25 02:48PM	Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025 (Insider Monkey)
02:03AM	Axsome Therapeutics Inc (AXSM) Q4 2024 Earnings Call Highlights: Robust Revenue Growth Amid ... (GuruFocus.com)
01:06AM	Q4 2024 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-18-25 11:15AM	Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript (Motley Fool)
07:00AM	Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-16-25 09:45AM	This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy? (Motley Fool)
Feb-11-25 02:42PM	Why Axsome Therapeutics (AXSM) Is Advancing Today (Insider Monkey)
11:39AM	Why Axsome Therapeutics Stock Is Soaring Today (Motley Fool)
03:33AM	Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains? (Zacks)
Feb-10-25 02:45PM	Why Axsome Therapeutics Stock Is Skyrocketing Today (Motley Fool) +20.16%
12:33PM	Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' (Benzinga)
07:00AM	Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY (dextromethorphan HBr bupropion HCl) Patent Litigation (GlobeNewswire)
Jan-31-25 07:00AM	Axsome Therapeutics Hosts SYMBRAVO FDA Approval Virtual Investor Event with Expert Thought Leader (GlobeNewswire)
Jan-30-25 03:45PM	Axsome Therapeutics Announces FDA Approval of SYMBRAVO (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults (GlobeNewswire)
Jan-22-25 07:00AM	Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18 (GlobeNewswire) +6.33%
Jan-13-25 04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily) +11.52% -5.23%
07:00AM	Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue (GlobeNewswire)
Dec-31-24 08:15AM	Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results (Benzinga)
Dec-30-24 05:07PM	Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation (Investor's Business Daily)
07:00AM	Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation (GlobeNewswire)
Dec-12-24 11:30AM	Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report? (Zacks)
Nov-27-24 01:23PM	Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says (Benzinga)
Nov-26-24 07:00AM	Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy (GlobeNewswire)
Nov-13-24 03:27AM	Q3 2024 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-12-24 03:15PM	Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript (Motley Fool) +9.35%
12:42PM	Axsome Hits 52-Week High After Surging Nearly 5%--FDA Milestones Could Fuel Even Bigger Gains (GuruFocus.com)
07:00AM	Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-08-24 07:00AM	Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 (GlobeNewswire)
Nov-05-24 10:00AM	Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-29-24 07:00AM	Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 (GlobeNewswire)
Oct-19-24 07:30AM	3 Bargain Stocks to Buy in a Market That's Priced for Perfection (Motley Fool)
Oct-15-24 07:00AM	Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12 (GlobeNewswire)
Sep-29-24 07:32AM	1 Under-the-Radar Biotech Stock to Buy and Hold (Motley Fool)
Sep-24-24 07:00AM	Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024 (GlobeNewswire)
Sep-04-24 07:00AM	Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine (GlobeNewswire) +6.59%
Aug-27-24 07:00AM	Axsome Therapeutics to Participate in Investor Conferences in September (GlobeNewswire)
Aug-21-24 07:00AM	Axsome Therapeutics Reaches Agreement to Dismiss Sunosi (Solriamfetol) Patent Litigation with Sandoz Inc. (GlobeNewswire)
Aug-16-24 05:43AM	Jim Cramer Thinks Axsome Therapeutics Inc (NASDAQ:AXSM) Stock Can Double (Insider Monkey)
Aug-05-24 01:45PM	Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript (Motley Fool)
12:15PM	Why Axsome Therapeutics Stock Is Sinking Today (Motley Fool)
11:30AM	Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates (Zacks)
07:00AM	Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-25-24 08:30AM	Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected (GlobeNewswire)
Jul-23-24 02:57PM	7 Biotech Stocks to Keep on Your Clinical Radar (InvestorPlace)
Jul-22-24 03:06PM	Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future (Benzinga)
Jul-15-24 07:15AM	Bull Market and Beyond: 2 Stocks Just Waiting to Soar (Motley Fool)
Jul-11-24 07:00AM	Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5 (GlobeNewswire)
Jul-05-24 02:14PM	The 3 Best Biotech Stocks to Buy in July 2024 (InvestorPlace)
Jul-04-24 10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
Jun-11-24 12:35PM	Why Axsome Therapeutics Stock Is Sinking Today (Motley Fool)
Jun-05-24 11:30AM	Axsome (AXSM) Down 6.1% Since Last Earnings Report: Can It Rebound? (Zacks)
07:35AM	Axsome Therapeutics Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories (GlobeNewswire)
Jun-04-24 07:00AM	Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month (GlobeNewswire)
Jun-03-24 07:00AM	Axsome Therapeutics Supports Alzheimer's & Brain Awareness Month (GlobeNewswire)
May-30-24 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-29-24 07:00AM	Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024 (GlobeNewswire)
May-28-24 07:00AM	Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting (GlobeNewswire)
May-18-24 06:47AM	3 Monster Stocks in the Making You Can Buy Right Now (Motley Fool)
May-13-24 07:57PM	15 Most Depressed States in the US (Insider Monkey)
May-11-24 10:00AM	The 3 Most Undervalued Biotech Stocks to Buy in May 2024 (InvestorPlace)
09:00AM	Prediction: These 2 Growth Stocks Could Triple By 2030 (Motley Fool)
May-08-24 07:00AM	Axsome Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pizzie Nick	Chief Financial Officer	Feb 13 '25	Option Exercise	3.50	12,000	42,000	54,187	Feb 14 09:20 PM
Pizzie Nick	Chief Financial Officer	Feb 14 '25	Option Exercise	3.50	3,000	10,500	45,187	Feb 14 09:20 PM
Pizzie Nick	Chief Financial Officer	Feb 13 '25	Sale	129.86	12,000	1,558,320	42,187	Feb 14 09:20 PM
Pizzie Nick	Chief Financial Officer	Feb 14 '25	Sale	131.07	3,000	393,210	42,187	Feb 14 09:20 PM
Pizzie Nick	Officer	Feb 14 '25	Proposed Sale	131.07	3,000	393,202		Feb 14 04:09 PM
Pizzie Nick	Officer	Feb 13 '25	Proposed Sale	129.86	12,000	1,558,312		Feb 13 04:02 PM
Coleman Mark	Director	Jan 03 '25	Option Exercise	9.00	9,127	82,143	57,137	Jan 06 04:06 PM
Coleman Mark	Director	Nov 19 '24	Option Exercise	5.94	33,410	198,455	48,010	Nov 20 04:30 PM
Saad Mark E	Director	Sep 11 '24	Option Exercise	3.67	11,016	40,429	21,018	Sep 11 07:00 PM
Saad Mark E	Director	Sep 11 '24	Sale	91.31	11,016	1,005,871	10,002	Sep 11 07:00 PM
Saad Mark E	Director	Sep 11 '24	Proposed Sale	91.31	11,016	1,005,843		Sep 11 04:32 PM
Jacobson Mark L.	Chief Operating Officer	Aug 09 '24	Option Exercise	4.04	47,739	192,866	53,522	Aug 09 07:27 PM
Jacobson Mark L.	Chief Operating Officer	Aug 09 '24	Sale	84.26	47,739	4,022,488	5,783	Aug 09 07:27 PM
Jacobson Mark L.	Officer	Aug 09 '24	Proposed Sale	84.26	47,739	4,022,490		Aug 09 05:07 PM
Jacobson Mark L.	Chief Operating Officer	May 29 '24	Option Exercise	1.30	13,693	17,801	13,693	May 29 08:12 PM
Jacobson Mark L.	Chief Operating Officer	May 29 '24	Sale	74.31	7,910	587,813	5,783	May 29 08:12 PM
Coleman Mark	Director	May 28 '24	Sale	75.21	5,249	394,775	19,848	May 29 08:11 PM
Coleman Mark	Director	May 29 '24	Sale	75.14	5,248	394,333	14,600	May 29 08:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AXSM

Axsome Therapeutics Inc

Upgrade your FINVIZ experience